Doug Manion - Articles and news items

Bristol Myers Squibb logo

ALLY Trial demonstrates high cure rates for investigational daclatasvir and sofosbuvir combination among genotype 3 hepatitis C patients

Industry news / 10 November 2014 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir (DCV) in combination with sofosbuvir (SOF) in genotype 3 hepatitis C (HCV) patients, a patient population that has emerged as one of the most difficult to treat…

Bristol Myers Squibb logo

Bristol-Myers Squibb to present at Bank of America Merrill Lynch Health Care Conference

Industry news, News / 10 May 2012 / Bristol-Myers Squibb Company

Doug Manion to will make a formal presentation…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...